Justyna Wilczko1, Cezary Szary1,2, Dominika Plucinska1, Tomasz Grzela1,3. 1. Clinic of Phlebology, 02-034 Warsaw, Poland. 2. Diagnostic Imaging Center MRI & CT, Center of Sport Medicine, 02-034 Warsaw, Poland. 3. Department of Histology & Embryology, Medical University of Warsaw, 02-004 Warsaw, Poland.
Abstract
BACKGROUND: The current treatment of venous disease is focused on the minimally invasive exclusion of the affected vein. Besides widely used thermal ablation, chemical ablation with cyanoacrylate, reported as safe and highly effective, has been gaining increasing interest. PATIENTS AND METHODS: In the current report, we present data from a two-year observation in 89 patients (61 female/28 male, mean age 44.3 ± 13.5) suffering from venous insufficiency (C2-C4), treated either using short-chain cyanoacrylate, the VenaBlock system (n = 43) or laser thermoablation with ELVeS 1470 (n = 46). The assessment comprised the occurrence of venous disease-related symptoms and the ultrasound examination of the leg venous system. RESULTS: The frequency of recanalization after 2 years from the VenaBlock procedure was significantly higher than after laser treatment (37.2 vs. 8.7%). Apart from recanalization, in some individuals from both groups, the symptoms of recurrence and/or disease progression, including the development of insufficiency in other veins of treated or contralateral legs (9.3 vs. 15.2% and 9.3 vs. 17.4%, respectively), were observed. Unexpectedly, the general prevalence of the disease progression did not differ significantly between the VenaBlock and ELVeS groups (44.2 vs. 34.8%, respectively). CONCLUSIONS: Despite the higher recanalization rate of VenaBlock compared to ELVeS, the overall effectiveness of cyanoacrylate and laser thermoablation after two years was similar. Therefore, both methods similarly failed to prevent recurrence and disease progression, which seem to be method-independent.
BACKGROUND: The current treatment of venous disease is focused on the minimally invasive exclusion of the affected vein. Besides widely used thermal ablation, chemical ablation with cyanoacrylate, reported as safe and highly effective, has been gaining increasing interest. PATIENTS AND METHODS: In the current report, we present data from a two-year observation in 89 patients (61 female/28 male, mean age 44.3 ± 13.5) suffering from venous insufficiency (C2-C4), treated either using short-chain cyanoacrylate, the VenaBlock system (n = 43) or laser thermoablation with ELVeS 1470 (n = 46). The assessment comprised the occurrence of venous disease-related symptoms and the ultrasound examination of the leg venous system. RESULTS: The frequency of recanalization after 2 years from the VenaBlock procedure was significantly higher than after laser treatment (37.2 vs. 8.7%). Apart from recanalization, in some individuals from both groups, the symptoms of recurrence and/or disease progression, including the development of insufficiency in other veins of treated or contralateral legs (9.3 vs. 15.2% and 9.3 vs. 17.4%, respectively), were observed. Unexpectedly, the general prevalence of the disease progression did not differ significantly between the VenaBlock and ELVeS groups (44.2 vs. 34.8%, respectively). CONCLUSIONS: Despite the higher recanalization rate of VenaBlock compared to ELVeS, the overall effectiveness of cyanoacrylate and laser thermoablation after two years was similar. Therefore, both methods similarly failed to prevent recurrence and disease progression, which seem to be method-independent.
Authors: Martin Lawaetz; Julie Serup; Birgit Lawaetz; Lars Bjoern; Allan Blemings; Bo Eklof; Lars Rasmussen Journal: Int Angiol Date: 2017-02-17 Impact factor: 2.789
Authors: Stefanie A Gauw; James A Lawson; Clarissa J van Vlijmen-van Keulen; Pascal Pronk; Menno T W Gaastra; Michael C Mooij Journal: J Vasc Surg Date: 2015-10-23 Impact factor: 4.268
Authors: Lakshmi A Ratnam; Petra Marsh; Judy M Holdstock; Charmaine S Harrison; Fuad F Hussain; Mark S Whiteley; Anthony Lopez Journal: Cardiovasc Intervent Radiol Date: 2008-08-28 Impact factor: 2.740
Authors: Cezary Szary; Justyna Wilczko; Dominika Plucinska; Anna Pachuta; Marcin Napierala; Anna Bodziony; Michal Zawadzki; Jerzy Leszczynski; Zbigniew Galazka; Tomasz Grzela Journal: J Clin Med Date: 2021-01-25 Impact factor: 4.241